ArticleOncology letters2026
Epithelioid and spindle cell rhabdomyosarcoma of the rib with FUS-TFCP2 fusion: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) with FUS RNA binding protein-transcription factor cellular promoter 2 (FUS-TFCP2) fusion is categorized as a subtype of spindle cell/sclerosing RMS. The current study reports a case of rib RMS with FUS-TFCP2 fusion in a 29-year-old male patient who presented with a rib mass that had existed for 3 months without causing any discomfort. A computed tomography scan revealed an occupying lesion at the second rib bone with a surrounding soft-tissue mass, along with left cervical lymph node metastasis. Histologically, the tumor was composed of fascicles of spindle to epithelioid cells, some of which showed eccentric nuclei resembling rhabdomyoblasts. The stroma was collagenous/sclerotic and occasionally myxoid. Immunohistochemistry revealed positive expression for desmin, myoblast determination protein 1 and smooth muscle actin, with partial expression of anaplastic lymphoma kinase, pan-CK and myogenin. Next-generation sequencing confirmed FUS-TFCP2 fusion and showed deletions in cyclin-dependent kinase inhibitor (CDKN)2A and CDKN2B. Fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.